Current Clinical Pharmacology

Continued as Current Reviews in Clinical and Experimental Pharmacology

Editor-in-Chief

Arduino A. Mangoni
Flinders University and Flinders Medical Centre
Adelaide, SA
(Australia)

Personal Subscription
Become EABM
Become Reviewer
Call for Editor
Volume: 5 Issue: 3, August

Editorial [Hot topic: Selected New Developments in Oncology (Guest Editors: Jos H. Beijnen and Jan H.M. Schellens)]

Volume:5   Issue: 3
Pp: 140-140
Jos H. Beijnen and Jan H.M. Schellens
DOI: 10.2174/157488410791498842
Published on: 01 March, 2012

Personalized Medicine in Oncology: A Personal View with Myths and Facts

Volume:5   Issue: 3
Pp: 141-147
Jos H. Beijnen and Jan H.M. Schellens
DOI: 10.2174/157488410791498789
Published on: 01 March, 2012

Monoclonal Antibody Therapy in Haematological Malignancies

Volume:5   Issue: 3
Pp: 148-159
Martine E.D. Chamuleau, Arjan A. van de Loosdrecht and Peter C. Huijgens
DOI: 10.2174/157488410791498752
Published on: 01 March, 2012

Monoclonal Antibodies in Solid Tumours

Volume:5   Issue: 3
Pp: 160-165
Ben Markman and Josep Tabernero
DOI: 10.2174/157488410791498833
Published on: 01 March, 2012

Molecular Targeted Therapy in Prevalent Tumors: Learning from the Past and Future Perspectives

Volume:5   Issue: 3
Pp: 166-177
Otto Metzger-Filho, Camilo Moulin and Ahmad Awada
DOI: 10.2174/157488410791498716
Published on: 01 March, 2012

Vascular Disrupting Agents (VDAs) in Anticancer Therapy

Volume:5   Issue: 3
Pp: 178-185
Laura G.M. Daenen, Jeanine M.L. Roodhart, Yuval Shaked and Emile E. Voest
DOI: 10.2174/157488410791498815
Published on: 01 March, 2012

Abrogation of the G2 Checkpoint by Inhibition of Wee-1 Kinase Results in Sensitization of p53-Deficient Tumor Cells to DNA-Damaging Agents

Volume:5   Issue: 3
Pp: 186-191
Suzanne Leijen, Jos H. Beijnen and Jan H.M. Schellens
DOI: 10.2174/157488410791498824
Published on: 01 March, 2012

Inducing Synthetic Lethality using PARP Inhibitors

Volume:5   Issue: 3
Pp: 192-195
David S. Boss, Jos H. Beijnen and Jan H.M. Schellens
DOI: 10.2174/157488410791498798
Published on: 01 March, 2012

Role of Histone Deacetylases and Their Inhibitors in Cancer Biology and Treatment

Volume:5   Issue: 3
Pp: 196-208
Jan H. Beumer and Hussein Tawbi
DOI: 10.2174/157488410791498770
Published on: 01 March, 2012

Pharmacogenetics of Irinotecan Disposition and Toxicity: A Review

Volume:5   Issue: 3
Pp: 209-217
Ken-ichi Fujita and Alex Sparreboom
DOI: 10.2174/157488410791498806
Published on: 01 March, 2012

DNA Vaccination in Oncology: Current Status, Opportunities and Perspectives

Volume:5   Issue: 3
Pp: 218-225
Joost H. van den Berg, Koen Oosterhuis, Jos H. Beijnen, Bastiaan Nuijen and John B.A.G. Haanen
DOI: 10.2174/157488410791498734
Published on: 01 March, 2012

Scheduling of Taxanes: A Review

Volume:5   Issue: 3
Pp: 226-231
Emma J. Woodward and Chris Twelves
DOI: 10.2174/157488410791498725
Published on: 01 March, 2012